Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Baveno VII consensus introduced the non-invasive criteria of clinically significant portal hypertension (CSPH) using liver stiffness measurement (LSM). We evaluated the usefulness of the Baveno VII criteria to predict the risk of decompensation in patients with compensated advanced chronic liver disease (cACLD).
Methods: We conducted a retrospective cohort study of 1966 patients with cACLD. Patients were categorized into four groups (CSPH excluded (n = 619), grey zone (low risk of CSPH (n = 699), high risk of CSPH (n = 207)), and CSPH included (n = 441)) according to Baveno VII consensus. The risk of events was estimated using a Fine and Gray competing risk regression analysis, with liver transplantation and death as competing events. We calculated standardized hazard ratios (sHR) to assess the relative risk of decompensation.
Results: Among 1966 patients, 178 developed decompensations over a median follow-up of 3.06 (IQR: 1.03-6.00) years. Patients with CSPH had the highest decompensation risk, followed by the grey zone high-risk group, grey zone low-risk group, and those without CSPH with 3-year cumulative risks of 22%, 12%, 3.3%, and 1.4% respectively (p < .001). Compared to CSPH excluded group, CSPH included group (sHR: 8.00, 95% CI: 4.00-16.0), grey zone high-risk group (sHR: 6.57, 95% CI: 3.16-13.6), grey zone low-risk group (sHR: 2.15, 95% CI: 1.04-4.41) had significantly higher risk of decompensation (Gray's test p < .01).
Conclusion: Non-invasive diagnosis of CSPH according to the Baveno VII criteria can stratify the risk of decompensation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.15632 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis.
Aliment Pharmacol Ther
August 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Background And Aims: Autoimmune hepatitis (AIH) may progress to advanced chronic liver disease (ACLD) with clinically significant portal hypertension (CSPH). In this study, we evaluated the prevalence of different clinical CSPH features and their prognostic impact regarding decompensation, liver transplantation (LTX) and death in patients with AIH.
Method: Patients with confirmed AIH diagnosis (sIAIHG-Score ≥ 6) managed at the Vienna General Hospital between 2005 and 2023 were retrospectively analysed.
Definition and validation of recompensation in patients with primary biliary cholangitis-related decompensated cirrhosis treated with ursodeoxycholic acid: Based on the BAVENO VII criteria.
J Transl Int Med
August 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University, Xi'an, Shaanxi Province, China.
Background And Objectives: Few studies have provided real-world data on the biochemical response, risk assessment, and prognosis of patients with primary biliary cholangitis (PBC)-related decompensated cirrhosis undergoing ursodeoxycholic acid therapy. The objective of this study is to define recompensation in this patient population based on the BAVENO VII criteria.
Methods: This retrospective analysis included 170 patients with cirrhosis who presented with ascites, hepatic encephalopathy, and/or variceal bleeding as their initial decompensating events at Xijing Hospital from 2006 to 2023.
Diagnostic Accuracy of Spleen-dedicated 100 Hz Transient Elastography to Predict High-risk Esophageal Varices.
Am J Gastroenterol
August 2025
Department of Gastroenterology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India, 751019.
Introduction: The Baveno VII consensus suggested different SSM cut-offs to predict High-Risk Esophageal Varices (HREV) and Clinically Significant Portal Hypertension (CSPH) in patients with cirrhosis. Few studies have validated these cut-offs using spleen-dedicated 100 Hz TE. We have assessed the diagnostic performance of SSM in predicting HREV and CSPH using a spleen-dedicated 100 Hz TE and compared it with other noninvasive algorithms.
View Article and Find Full Text PDFFuture research direction of portal hypertension based on Baveno VII.
Chin Med J (Engl)
August 2025
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Clínic Barcelona, ERN-RareLiver (Health Care Provider of the European Reference Network on Rare Liver Disorders), CSUR Centro de referencia del Sistema Nacional de Salud en Enfermedad Hepática Vascular Compleja en adultos. Ba
The Baveno Cooperation is a consortium of internationally renowned experts committed to setting standards for the clinical management of patients with advanced chronic liver disease, with a particular emphasis on complications related to portal hypertension. Updated every five years and endorsed by major scientific societies, the Baveno recommendations have significantly influenced clinical practice and improved patient outcomes worldwide. The latest Baveno consensus, Baveno VII, provided a series of recommendations that have shifted our understanding of chronic liver disease and portal hypertension and profoundly shaped clinical practice.
View Article and Find Full Text PDFRecompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy.
JHEP Rep
September 2025
Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Shanghai Institute of Digestive Disease, Shanghai, China.
Background & Aims: In this study, we aimed to evaluate the incidence, predictors, and prognostic significance of recompensation in autoimmune hepatitis (AIH)-related decompensated cirrhosis following immunosuppressive therapy (IST).
Methods: We retrospectively analyzed patients with AIH at first decompensation. Recompensation, defined using modified Baveno VII criteria, required clinical resolution (≥12 months without ascites, variceal bleeding, or hepatic encephalopathy, with liver function restored to Child-Pugh A) along with aetiological suppression (complete biochemical response under IST).